Conditions & Recovery · ASCO Daily News · October 15, 2026

ASCENT and DESTINY-Breast09 Trials: Applying Frontline Data in Metastatic Breast Cancer Care

Dr. Sara Tolaney joins Dr. Monty Pal to discuss optimizing the sequencing and combination of antibody-drug conjugates for metastatic HER2-positive and triple-negative breast cancer, as well as guidelines for managing serious toxicities like ILD and neutropenia. LINK TO FULL TRANSCRIPT

Originally published by ASCO Daily News. We curate and add context; they did the reporting.

Related learning